Hyposensitivity Rabies Vaccine

People with allergies often experience allergic reactions to conventional rabies vaccines due to components such as bovine serum and gelatin, facing a dilemma of fearing allergic reactions from vaccination or fearing disease if not vaccinated. The Hyposensitivity Rabies Vaccine provided by AIM Honor, a Chinese manufacturer, meets the core requirements of no added allergens, low impurity residue, and high immunogenicity. It supports the WHO's simplified 4-dose regimen, making it the preferred choice for post-exposure prophylaxis in people with allergies.

Immunization Dilemma of People with Allergic Constitution

When people with allergic constitution are vaccinated with conventional rabies vaccines, they are prone to allergic reactions due to components such as bovine serum and gelatin in the vaccines. Mild cases may have urticaria, while severe cases may induce anaphylactic shock. As a result, such people are caught in a dilemma of afraid of allergy if vaccinated, afraid of onset if not vaccinated after exposure.

Core Requirements for Hyposensitivity Vaccines

No Allergens Added: Common sensitizing components such as bovine serum and heterologous proteins must be removed.

Low Impurity Residue: Strictly control the residues of exogenous proteins and nucleic acids in the vaccine.

High Immunogenicity: While ensuring hyposensitivity, ensure that the antibody level meets the standard.

AIM Serum-free Rabies Vaccine: Exclusive Protection for People with Allergic Constitution

AIM's Serum-free Vero Cell Rabies Vaccine is a typical hyposensitivity rabies vaccine, with the following core advantages:

Avoid Sensitization Risks from the SourceIt adopts a serum-free culture process throughout the production, without adding bovine serum in the production process, completely eliminating the sensitization risk of bovine-derived proteins; meanwhile, the dosage of auxiliary materials such as gelatin is strictly controlled, and the vaccine purity far exceeds the industry standard. Clinical verification shows that the incidence of allergic reactions in people with allergic constitution after vaccination is <0.5%, all of which are mild urticaria and can be relieved quickly

Balance Hyposensitivity and High EfficiencyThis vaccine achieves a 100% antibody seroconversion rate 14 days after vaccination, with a neutralizing antibody GMC (Geometric Mean Concentration) of 32.76IU/mL, and supports the WHO Simplified 4-dose Schedule. It not only meets the hyposensitivity requirements, but also provides strong and long-term immune protection, and has become the first choice for post-exposure prevention in people with allergic constitution